• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物群:肠道疾病的病因和治疗方法。

The gut microbiota: cause and cure of gut diseases.

机构信息

Nambour General Hospital, Nambour, QLD

Sunshine Coast University Hospital, Sunshine Coast, QLD.

出版信息

Med J Aust. 2018 Sep 1;209(7):312-317. doi: 10.5694/mja17.01067.

DOI:10.5694/mja17.01067
PMID:30257633
Abstract

The gastrointestinal microbiota is emerging as a central factor in the pathogenesis of a range of gastrointestinal and hepatic disorders. Epidemiological studies, and experimental studies in animals and humans, have highlighted a likely causative role of this microbial community in the modern global epidemics of inflammatory bowel disease, non-alcoholic fatty liver disease, non-alcoholic steato-hepatitis, obesity and metabolic syndrome. New techniques for microbial culture and gene sequencing are enabling the identification of specific pathogens and protective organisms in these conditions. Factors that change the microbiota are being defined: dietary pattern, specific foods, food additives in processed food and drinks, such as emulsifiers and non-sugar sweeteners, and antibiotics. Microbiota changes in early life appear critical to the later development of a range of inflammatory disorders. For many of these conditions, the treatment paradigm will change, at least in part, from immune suppression and drug therapy to treatments that reshape the microbiota or restore its integrity. These treatments include dietary changes, specific microbial manipulation and faecal microbiota transplantation. A dialogue is needed regarding population strategies that target disease prevention. This will include how food is produced, what additives it contains, and how it is processed. Widespread use of antibiotics, from agricultural and veterinary to medicinal settings, needs more attention. At the individual level, microbial profiles may be able to predict who is at risk of disease when subjected to particular environmental influences, and what microbial restoration is needed to minimise risk.

摘要

肠道微生物群正在成为一系列胃肠道和肝脏疾病发病机制的核心因素。流行病学研究以及动物和人类的实验研究强调了这种微生物群落可能在炎症性肠病、非酒精性脂肪性肝病、非酒精性脂肪性肝炎、肥胖和代谢综合征等现代全球流行病中起致病作用。微生物培养和基因测序的新技术使人们能够在这些疾病中识别出特定的病原体和保护生物。正在定义改变微生物群的因素:饮食模式、特定食物、加工食品和饮料中的食品添加剂,如乳化剂和非糖甜味剂以及抗生素。早期生活中的微生物群变化似乎对一系列炎症性疾病的后期发展至关重要。对于许多这些疾病,治疗模式将发生变化,至少部分将从免疫抑制和药物治疗转变为重塑微生物群或恢复其完整性的治疗方法。这些治疗方法包括饮食变化、特定微生物操作和粪便微生物群移植。需要就针对疾病预防的人群策略进行对话。这将包括食物的生产方式、所含添加剂以及加工方式。从农业、兽医到医疗领域广泛使用的抗生素需要更多关注。在个体层面上,微生物特征可能能够预测在受到特定环境影响时谁有患病风险,以及需要进行哪些微生物恢复以最小化风险。

相似文献

1
The gut microbiota: cause and cure of gut diseases.肠道微生物群:肠道疾病的病因和治疗方法。
Med J Aust. 2018 Sep 1;209(7):312-317. doi: 10.5694/mja17.01067.
2
Fecal microbiota transplantation for gastrointestinal disorders.用于胃肠道疾病的粪便微生物群移植
Curr Opin Gastroenterol. 2017 Jan;33(1):8-13. doi: 10.1097/MOG.0000000000000326.
3
Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease.炎症性肠病中肠道微生物群的特征分析与治疗调控
Intern Med J. 2016 Mar;46(3):266-73. doi: 10.1111/imj.13003.
4
Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT).肠道微生物群与肥胖:通过粪便微生物群移植(FMT)改变肥胖的机会。
Diabetes Obes Metab. 2019 Mar;21(3):479-490. doi: 10.1111/dom.13561. Epub 2018 Nov 20.
5
The Gut Microbiome and Probiotics.肠道微生物群与益生菌
Adolesc Med State Art Rev. 2016 Spring;27(1):140-54.
6
Dysbiosis in gastrointestinal disorders.胃肠道疾病中的微生物群落失调。
Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):3-15. doi: 10.1016/j.bpg.2016.02.001. Epub 2016 Feb 16.
7
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.槲皮素对高脂饮食诱导的小鼠非酒精性脂肪性肝病的保护作用是通过调节肠道微生物群失衡和相关肠-肝轴激活来介导的。
Free Radic Biol Med. 2017 Jan;102:188-202. doi: 10.1016/j.freeradbiomed.2016.11.037. Epub 2016 Nov 25.
8
Gut microbiota and health.肠道微生物群与健康。
Postgrad Med. 2020 Apr;132(3):274. doi: 10.1080/00325481.2019.1662711. Epub 2019 Sep 28.
9
The gut microbiome.肠道微生物群
Aust Fam Physician. 2017;46(4):206-211.
10
Gut microbiota and obesity: implications for fecal microbiota transplantation therapy.肠道微生物群与肥胖:粪便微生物群移植治疗的启示。
Hormones (Athens). 2017 Jul;16(3):223-234. doi: 10.14310/horm.2002.1742.

引用本文的文献

1
Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota.肠道微生物群在肝细胞癌中的作用:从肠道生态失调到肿瘤内微生物群。
Cell Death Discov. 2025 Apr 4;11(1):140. doi: 10.1038/s41420-025-02413-z.
2
Therapeutic potential of in gastrointestinal and hepatic disease.[具体物质]在胃肠和肝脏疾病中的治疗潜力。 (原文中“in”前面缺少具体内容,这里用“[具体物质]”代替以便完整表达意思)
MedComm (2020). 2024 Dec 16;5(12):e70017. doi: 10.1002/mco2.70017. eCollection 2024 Dec.
3
Microbial metabolites in colorectal tumorigenesis and cancer therapy.
肠道肿瘤发生和癌症治疗中的微生物代谢产物。
Gut Microbes. 2023 Jan-Dec;15(1):2203968. doi: 10.1080/19490976.2023.2203968.
4
Therapeutics in Metabolic Diseases.代谢性疾病的治疗学
Adv Exp Med Biol. 2023;1396:255-273. doi: 10.1007/978-981-19-5642-3_17.
5
Gut Microbiota Differences According to Ultra-Processed Food Consumption in a Spanish Population.根据西班牙人群的超加工食品消费情况分析肠道微生物群的差异。
Nutrients. 2021 Aug 6;13(8):2710. doi: 10.3390/nu13082710.